通过一种基于活性阴离子聚合的新的迭代方法,已成功实现了明确定义的星形支化聚合物的连续合成。该方法仅涉及整个重复反应序列的两组反应条件:(a)苄基溴官能化的聚合物与封端有1-(3-叔丁基二甲基二甲基甲硅烷氧基甲基苯基)-的聚(取代的苯乙烯基)锂的偶联反应1-苯基乙烯连接两个聚合物链并引入苄基溴前体的3-叔丁基二甲基甲硅烷氧基甲基苯基和(b)引入的前体通过苯甲酰胺处理转化为苄基溴官能度(官能度)的反应(CH 3)3SiCl-LiBr。通过重复这两个反应,连续合成了一系列不对称的星形支化聚合物。他们涉及3臂ABC,4臂ABCD和A 2 B 2以及6臂A 2 B 2 C 2星,它们的A,B,C和D段为聚苯乙烯,聚(α-甲基苯乙烯),聚(分别为4-甲基苯乙烯),聚(甲基丙烯酸甲酯)或聚(甲基丙烯酸叔丁酯)。它们的高度的组成,分子量,和建筑同质性以及窄的分子量分布(中号瓦特/中号Ñ <1.05)通过SEC,的分析结果确认11
通过一种基于活性阴离子聚合的新的迭代方法,已成功实现了明确定义的星形支化聚合物的连续合成。该方法仅涉及整个重复反应序列的两组反应条件:(a)苄基溴官能化的聚合物与封端有1-(3-叔丁基二甲基二甲基甲硅烷氧基甲基苯基)-的聚(取代的苯乙烯基)锂的偶联反应1-苯基乙烯连接两个聚合物链并引入苄基溴前体的3-叔丁基二甲基甲硅烷氧基甲基苯基和(b)引入的前体通过苯甲酰胺处理转化为苄基溴官能度(官能度)的反应(CH 3)3SiCl-LiBr。通过重复这两个反应,连续合成了一系列不对称的星形支化聚合物。他们涉及3臂ABC,4臂ABCD和A 2 B 2以及6臂A 2 B 2 C 2星,它们的A,B,C和D段为聚苯乙烯,聚(α-甲基苯乙烯),聚(分别为4-甲基苯乙烯),聚(甲基丙烯酸甲酯)或聚(甲基丙烯酸叔丁酯)。它们的高度的组成,分子量,和建筑同质性以及窄的分子量分布(中号瓦特/中号Ñ <1.05)通过SEC,的分析结果确认11
New pesticidal e.g. insecticidal, compounds are of formula ##STR1## wherein X represents hydrogen, halogeno or an alkyl group, Z represents hydrogen, an alkyl group or a cyano or ethynyl group and R represents the residue of a carboxylic acid RCOOH which is an acid forming a pesticidal compound when esterified with .alpha.-cyano-3-phenoxybenzyl alcohol. The compounds can be prepared by conventional methods e.g. esterification.
styrene and vinylarenes, the aryl and vinyl groups routinely insert at the β position. However, selective insertion at the αposition has been very rare. Herein, we provide a missing piece in the palette of Heck reaction, which gave >20:1 αselectivity. The key to our success is a new ferrocene 1,1′‐bisphosphane (dnpf) that carries 1‐naphthyl groups. Our mechanistic studies revealed that the high α selectivity
SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS
申请人:Zhi Lin
公开号:US20110003851A1
公开(公告)日:2011-01-06
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.
The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.